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Drug metabolism in the elderly: a multifactorial problem? 
R.H. Waring a, R.M. Harris a, S.C. Mitchell b     
a School of Biosciences, University of Birmingham, Birmingham, UK 
b Computational and Systems Medicine, Imperial College London, London, UK 
 
Highlights 
 Drug metabolism in healthy old age is similar to that found in young adults. 
 Drug metabolism may be reduced in elderly subjects who are frail and/or ill. 
 Adverse drug reactions in elderly patients are not predictable on current models. 
 
Abstract 
Whether or not an individual’s drug metabolising capacity declines with advancing age is a 
vexing question. There is no clear evidence that drug metabolism itself (‘the biologically-
assisted chemical alteration of the administered parent molecule’) is less efficient in healthy 
old age than at younger ages, whereas a decreased capacity may be associated with ill-health 
and frailty. However, elderly individuals do show a reduced enzyme induction capability and 
are less able to tolerate overdoses. It appears that the majority of deleterious clinical outcomes 
related to drug therapy in an elderly (usually ill or frail) population may be ascribed to various 
anatomical and physiological age-related changes. These may affect both pharmacodynamics 
and pharmacokinetics, but not necessarily drug metabolism. Information gleaned from animal 
studies undertaken mainly in rodents does not seem to be of relevance to humans and studies 
in healthy aged human populations may not highlight possible problems. However, certain 
circumstances may influence metabolic competence, and phenotyping rather than genotyping 
is of more value in identifying those susceptible to adverse drug reactions. This short review 
discusses the potential contributions of four factors (inflammation, circadian rhythm, gut 
microbes, epigenetic aspects) which may lead to alterations in drug metabolism with increasing 
age. 
Keywords: age effect; xenobiosis; inflammation; circadian rhythm; gut microbiota; 
epigenetic factors 
Introduction 
Many interacting factors influence the journey of a drug through the human body and age‐
related changes may lead to differences in an older subject’s ability to process and respond to 
drugs when  compared  to  a  younger  cohort. As  time passes,  anatomical  and physiological 
changes take place within several body organs and a general alteration of body composition 
occurs,  all  aspects  which  may  influence  drug  pharmacokinetics  and  pharmacodynamics, 
potentially leading to a variety of clinical outcomes (Table 1). 
This  short  review  concerns  itself with one of  these aspects, namely drug metabolism,  the 
‘biologically‐assisted chemical alteration of the administered parent drug molecule’. It should 
be appreciated that although there may be general trends, many factors (both genetic and 
environmental)  will  influence  a  particular  individual’s  situation  and  that  knowledge  of  a 
subject’s chronological age may not be a true indicator of their functional biological age. This 
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is certainly true  if they have been exposed to a previous chemical background, are of poor 
nutritional status or have suffered ill health [1‐4]. 
Drug metabolism  in the elderly  (more than 65 years old)  is of particular  interest since this 
group is forming an increasingly larger part of the population. People are living longer thanks 
to  modern  drug  discoveries  and  to  ‘polypharmacy’  where  individuals  have  multiple 
prescriptions increasing the potential for drug‐drug interactions. However, although the aged 
are  prescribed  more  drugs  than  other  sections  of  the  population,  it  is  rare  to  find  that 
therapies are trialled in this age‐group during the drug development process. In most Western 
countries, adverse drug reactions  (ADRs) account  for c.10% of hospital admissions and the 
elderly are over‐represented in this category. The question therefore arises as to whether or 
not  they  have  specific  patterns  of  drug  metabolism  which  reduce  their  ability  for 
detoxification and if so, what circumstances might be involved.  
Drug metabolism 
Absorption of a compound is more readily achieved if it is lipid-soluble whereas excretion is 
facilitated by water-solubility. Hence the body, with a quest for maintaining the status quo, 
being ‘assaulted’ by a lipid-soluble molecule, strives to increase its water solubility via 
chemical modification and, perhaps by default, also reduce its pharmacological interaction. The 
pathways of drug, or xenobiotic metabolism, have been assigned traditionally to one of two 
categories or phases. In Phase I metabolism, the drug is generally made more water-soluble, 
usually by modifications such as hydrolysis or hydroxylation via the cytochrome P-450–linked 
family of enzymes (CYP450). Phase II typically involves masking chemically reactive groups 
and increasing polarity by linking the parent drug or its metabolite from Phase I with some 
large water-soluble anion from endogenous metabolism such as sulfate or glucuronic acid 
(Figure 1). 
Phase I metabolism and age 
Animal models 
That age may affect drug metabolism was demonstrated over fifty years ago [5] and since that 
time many studies, mainly in rodents, have confirmed these initial observations [6]. It is widely 
accepted that the overall trend is for a decrease in metabolism as the animals move from 
maturity into senescence [7]. For those reactions involving the mixed function oxidases, mainly 
CYP450, this is generally correct for the male rat although increases have been reported for 
some compounds. In the female rat, most activities remained constant except for decreases in 
some dealkylation reactions including aminopyrine [8], though other workers reported an 
increase for this compound [9]. A more confused situation exists for the mouse where increases, 
decreases and no changes have been reported with these results sometimes varying between 
different studies [7]. Probable animal strain differences are undoubtedly important here. 
Human studies 
Following drug administration, the majority of studies in man have measured blood and 
sometimes urine levels of the unchanged compound and then calculated various 
pharmacokinetic parameters, such as the maximum plasma concentration (Cmax), plasma 
elimination half-life (t½), area under the concentration/time curve (AUC) or clearance (CL). 
These values are composites that reflect the many processes influencing the passage of a drug 
through the body and where drug metabolism may only play a minor role. The use of test 
compounds of previously known high hepatic clearance (extraction) may offset some of these 
difficulties but the results are still not necessarily indicative of drug metabolism. For example, 
pharmacokinetic studies employing the ‘model drug’ antipyrine as a global measure of Phase I 
drug metabolism (metabolic pathways involving CYP3A4, CYP1A2, CYPC8/9) have shown 
both increases and decreases in its clearance with advancing age [10,11]. 
Early studies using human liver biopsies found no significant correlation between age and 
overall cytochrome P450 content, or any decrease in aldrin epoxidation or 7-ethoxycoumarin-
O-deethylation [12,13]. Similarly, no age related declines in drug microsomal enzyme activity 
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were detected in primates [14,15]. Other investigations have shown that total microsomal P450 
levels were not particularly reduced with age [16,17] and that the activities of various CYP450 
isozymes including 1A2, 2A6, 2B6, 2C, 2D6, 2E1 and 3A4, in human hepatic microsomes 
showed no marked differences in older subjects [16,18-20]. The hydrolysis enzymes, benzoyl, 
butyryl and acetylcholine esterases also show no decline in activity with age [21]. This implies 
that Phase I metabolism itself is unimpaired in the healthy elderly population [22-24]. 
Phase II metabolism and age 
Animal models 
Amongst the conjugation reactions, glucuronic acid condensation appears little changed in 
rodents and only minor perturbations were observed with glutathione conjugation whereas 
several groups reported that sulfation (sulfonation) of paracetamol decreased. The sulfation of 
nitrophenol also decreased in the male rat [25] but increased in the mouse [26]. Again, there 
were no overarching patterns. 
Human studies 
Investigations in humans suggest that Phase II metabolism is relatively well-preserved in aging 
populations. A study employing paracetamol demonstrated that no correlation existed between 
old age and glucuronidation or sulfation reactions, indicating that age itself does not lead to a 
decrease in these activities in man [27]. The present authors compared the metabolism of 
paracetamol in a small healthy student population (age 18-22 years) with two geriatric 
populations (age 75-85 years). The excretion of glucuronide and sulfate metabolites in the 
elderly cohort taking no other medications was not significantly different from values in the 
student population whilst there were reductions of 30-35% in glucuronide and sulfate excretion 
for the elderly cohort who were in ill health and taking an average of 5.2 prescription drugs 
each. This may reflect either the polypharmacy or the underlying physiological dysfunction in 
the latter group. In the healthy aged there is no evidence of any effects on the pathway of 
glutathione conjugation and there appears to be no reduction of hepatic reduced glutathione 
[13]. 
Factors potentially affecting drug metabolism with age 
As well as the previously mentioned anatomical and physiological features that alter with 
increasing age (Table 1), there are a few other aspects, less well recognised, that should be 
considered with regard to drug metabolism. However, this is not meant to imply that they may 
not have influence at any of the other stages of a compound’s progress through the body, 
namely; absorption, distribution, metabolism and excretion (ADME).  
Inflammation 
Inflammatory states become more common as individuals age, with many maladies having 
distinct inflammatory components that signal the development and progression of the disease 
[28]. Upsurges in inflammatory activity have been observed in the earliest phases of dementia 
including Alzheimer’s disease, and also in type 2 diabetes and Metabolic Syndrome as well as 
with chronic obstructive pulmonary disease and during bouts of rheumatoid and osteoarthritis. 
Such situations may compromise the ADME enzymes and inflammation has been shown both 
in vivo and in vitro to regulate the CYP isoforms which carry out Phase I metabolism [29]. 
Phase II metabolism may also be affected; the sulfation pathway is known to be reduced in 
inflammation, probably by the release of cytokines [30] whilst in vitro studies suggest that 
formation of glucuronide and glutathione metabolites may be reduced [31]. Frailty is associated 
with higher inflammatory markers and lower esterase activity [32] so these findings may be a 
partial explanation of the increased rate of ADRs in elderly patients. 
Circadian rhythms 
Circadian regulation is mediated through the suprachiasmatic nucleus (SCN) which acts as the 
master controller, combining environmental cues from light and food intake to entrain internal 
clocks [33]. Drug absorption is known to have a circadian variation; lipophilic drugs are 
absorbed faster when taken in the morning although there is no circadian variation in absorption 
of water-soluble compounds. Drug metabolism also varies with the time of day and expression 
of the cytochrome P450 gene family is regulated by the biological clock. In turn, in a feedback 
loop with a period of about 24 hours, these monooxygenases metabolise melatonin, the pineal 
hormone which resets the biological clock. This potential variation is particularly important if 
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the parent drug or metabolites are toxic and there are clinical guide lines on the optimum timing 
of drug dosing for many compounds including anti-cancer, cardiovascular, anti-inflammatory, 
antiepileptic and immuno-suppressive agents [34,35]. However, disturbed circadian rhythms 
are more common in elderly populations in general and less stable patterns are linked with 
increased mortality. Dysregulation of the biological clock is associated with depression and 
anxiety and also with neurological disorders and cancer [36,37]. The elderly may therefore not 
respond to the standard recommended timings for medication and are potentially more at risk 
from ADRs. 
Gut microbiota 
The microbial ecosystem that exists within the human gastrointestinal tract is of great interest 
and known to be important in the maintenance of human health, since it appears to modulate 
innate immunity and probably cognitive function as well as assisting in nutritive processes. 
These microbes are thought to account for up to 90% of the cells present in a human organism 
and, although rapid advances are now being made, relatively little is understood about the 
composition of the gut microbiome with only about 30% being identified. However, it is 
appreciated that gut bacteria do play a part in drug metabolism and, as they are largely 
anaerobic, they usually participate in reactions involving chemical reduction or fission of 
molecules. For instance, the metabolism of epacadostat, a potential immunomodulatory and 
antineoplastic agent, in humans involves formation of an amidine metabolite by gut bacteria 
(N-OH to N-H) which is then absorbed and further metabolised via side-chain dealkylation by 
CYP450 [38]. Many other clinically-relevant drugs are known to be co-metabolized by host 
and gut microflora [39]. Clearly, if composition of the gut microbiome changes, and this is 
known to occur with aging (particularly Bifidobacterum spp.), particularly amongst frail 
individuals and long-stay residents in care homes, then drug metabolism may be altered also 
with ensuing consequences [40,41]. 
Epigenetics 
Perturbations encompassing the hereditary material deoxyribonucleic acid (DNA) that do not 
involve actual sequence changes, but affect gene expression and cellular phenotypes, are termed 
‘epigenetic’. Many modifications are known to occur, including the addition of methyl groups 
to the cytosine or guanine residues (CpG islands) within the DNA molecule and histone 
acetylation and methylation, potentially leading to an overall remodelling of the chromatin 
package (histone/DNA complex). Also, the production of non-coding ribonucleic acid 
molecules (ncRNAs) which are functional, but not translated directly into a protein, is able to 
modulate the transcriptional and post-transcriptional regulation of gene expression in a variety 
of ways. Studies on older populations (>75 years) confirmed that there were age-related 
changes in DNA methylation patterns at specific CpG islands and that high methylation levels 
were linked to a subsequent diagnosis of cancer [42]. Specific epigenetic changes in DNA 
methylation in brain and peripheral blood leukocytes have also been noted in patients with 
Parkinson’s disease [43] in line with abnormal patterns of drug methylation. 
Epigenetic regulation of ADME genes is an area of great interest. Much of the work has been 
undertaken in tumour cell lines which obviously may not be representative of the normal 
healthy in vivo situation. Nevertheless, it is clear that both Phase I and II reactions are affected 
[44] although the research has generally focused on the CYP450 isoforms. The human CYP2C9 
gene is involved in metabolism of many pharmaceuticals and endogenous substrates and its 
activity has been shown to be easily inducible and also regulated by epigenetic mechanisms. 
The expression of both CYP1A1 and CYP1B1 genes is similarly highly inducible, especially 
by dioxins and polycyclic hydrocarbons. Regulation of CYP3A4 is also epigenetic in man and 
its silencing in human foetal liver has been linked with the DNA hypermethylation of certain 
CpG sites close to key gene regulatory elements. During development demethylation occurs 
with a consequent increase in activity and once adult levels are attained there appears to be no 
significant variation in CYP3A4 expression [45]. Nevertheless, it may be appreciated that 
subsequent methylation in the elderly (like the foetal situation) could be a mechanism to reduce 
activity. 
It has been appreciated for some time that elderly individuals have a reduced enzyme induction 
capability and are less able to tolerate overdoses [46]. This may reflect increased epigenetic 
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gene silencing with age since DNA methylation was shown to inhibit subsequent attempts at 
dioxin-mediated induction of the CYP 1B1 gene activity. Environmental contaminants are 
known to be involved in alterations to gene expression (common pollutants such as bisphenol 
A can have epigenetic effects) and, as elderly patients will have had more potential exposure to 
such chemicals, there may be a general phenomenon of altered methylation patterns with time. 
Such changes have been reported as reflecting differential biological aging [47,48].  
Conclusion 
Much work on drug metabolism in elderly mammalian populations has been undertaken on 
rodents and there is relatively little available information for humans. Unfortunately, gender 
differences in metabolism are pronounced in rats and mice and any attempt at extrapolation to 
man is fraught with difficulties, if not meaningless. This problem has been subtly stated in an 
alliterative manner, the “effect of senescence seems to depend upon species, strain, sex and 
substrate” [49]. Seemingly, the only true model for man is man. 
The literature, understandably, has relatively few examples where drugs are administered to 
healthy but elderly populations. However, it is clear that any changes in drug metabolism with 
age are less obvious in such populations but are important potentially in those who are already 
frail or ill, in other words, the targets for drug therapy. This is reasonable since the metabolic 
pathways of both xenobiotics such as drugs and environmental contaminants and endogenous 
compounds such as steroids are essentially inter-related. Factors affecting health will 
potentially also affect the therapeutic agents which are prescribed. Epigenetic regulation of 
ADME-related genes is obviously more likely in an aging population with an increased 
exposure to environmental factors affecting gene expression; this area is currently of 
considerable interest and future work will certainly clarify the situation. A further complication 
is that drug testing in elderly rodents is unlikely to give useful information on human responses 
and even testing in elderly but healthy humans will not mirror the situation for the target group 
for therapy, the frail hospitalised patient. It may never be possible to predict ADRs. 
Generally, decreased drug metabolism as such is not the major causative factor in the differing 
clinical responses observed in elderly subjects. However, frail and ill individuals do have 
increased susceptibility and their overall responses reflect the complex interplay existing 
between many genetic and environmental influences.  
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Figure Legend 
Figure 1 
The major routes of absorption, distribution, metabolism and excretion available to a drug 
following oral administration.   
Microfloral Metabolism
(Mainly reductive and hydrolytic)
Phase II Metabolism
(Conjugation with glutathione;
glucuronic, sulfonic or amino 
acids; acetyl or methyl groups)
Phase I Metabolism
(Mainly oxidative, reductive 
or hydrolytic)
Excretion
(Diffusion or active transport)
Bile Kidney
Faeces Urine
Drug
Absorption
(Diffusion or active transport)
Tissue Binding
(Mainly plasma proteins,
adipose and bone)
 
Table 1. Factors that may influence drug pharmacokinetics and pharmacodynamics in an 
elderly population 
 
Absorption 
Alteration in gastric and intestinal motility * 
Variable rate of gastric emptying, lower gastric acid secretion * 
Decreased absorptive surface of small intestine * 
Decreased splanchnic blood flow* 
 
Distribution  
Lowering of total body water content 
Reduced lean body mass, increase in adipose tissue 
Altered plasma-protein binding * 
 
Metabolism 
Decrease in hepatic blood flow 
Decrease in liver size and number of functional hepatic cells 
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Changes in enzyme activity 
Changes in gut microbiome 
 
Excretion 
Decrease in renal mass 
Reduction in renal perfusion 
Glomerular filtration rate falls 
Tubular excretory/secretory function falls 
Alteration in biliary secretion efficiency* 
 
Organ sensitivity 
Changes in receptor sensitivity 
Adaptive response to previous exposure 
Alteration in blood-brain barrier shield, increased CNS sensitivity 
Accumulated damage to cellular functions 
 
Other factors 
General nutritional status 
Chronic disease states 
Life-style habits, physical exercise and general fitness 
Previous chemical exposure 
Compliance: overdose / underdose 
 
* The literature contains conflicting reports as to the significance of these effects in the 
elderly [1]. 
 
 
 
